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THE COST-EFFECTIVENESS OF PROSTATE-SPECIFIC
ANTIGEN SCREENING FOR PROSTATE CANCER DETECTION
Tencer T, Hay JW
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To compare the cost-effectiveness of PSA screen-
ing for the detection of prostate cancer in the United States versus
no screening. Incremental Cost per Quality-Adjusted Life Year
(QALY) using a lifetime decision model was used. METHODS:
Estimates of cost, utility and probabilities were taken from lit-
erature, clinical experts and the Bureau of Labor Statistics.
Cancer speciﬁc mortality rates were determined by the grade of
the disease. The DEALE method was used to calculate average
life expectancy of men in the general population, using the life
tables from the CDC. A cohort of men stratiﬁed into six age
groups: 45–59, 50–54, 55–59, 60–64, 65–69, and 70–74. The
time horizon was a lifetime; future values discounted at 3% and
the perspective was societal. RESULTS: In 2002 USD, a one time
screening of each age group was found to be cost-effective. The
incremental cost-effectiveness ratio (ICER) ranged from $5291
per life year saved for men aged 45–49 to $12,219 per life 
year saved for men aged 70–74. After adjusting for quality of
life, we found that the ICER ranged from $6,452/QALY to
$14,902/QALY for men aged 70–74. Results of sensitivity analy-
sis show lowering the positive predicted value of the PSA test by
approximately 30% increased cost/QALY from 8–12%, increas-
ing it by about 20% decreases the ratio about 3–5%. The model
remained cost-effective after varying the cost of Radical Prosta-
tectomy, the mortality from surgery and the percentage of local
prostate cancers found by screening. CONCLUSION: This
model found a one time PSA screening for prostate cancer in each
age group to be cost-effective relative to no screening.
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THE COST-EFFECTIVENESS OF HERCEPTIN® IN ADJUVANT
SETTING: THE HERA TRIAL
Neyt M1, Cocquyt V2,Albrecht J1
1Ghent University, Gent, Belgium; 2University Hospital Gent, Gent,
Belgium
OBJECTIVES: Trastuzumab as adjuvant therapy is being tested
in a number of large randomised trials. Our purpose is to cal-
culate the cost implications of using trastuzumab as in the HerA
trial and provide information on the product’s value for money.
METHODS: Standard breast-cancer treatment models were set
up for different subpopulations according to stage (I, II, III) and
menopausal condition (·,Ò 50 years). They were constructed from
the hospital’s point of view to analyse the impact of new treat-
ments on real costs. Costs were calculated using the micro-
costing method and gathered in close collaboration with the staff
of our treatment centre. The comparator or benchmark in our
analysis was the existing practice. On the basis of the HerA trial
and experts opinions, trastuzumab monotherapy was imple-
mented in our treatment model. In addition to a sensitivity analy-
sis, a threshold analysis was performed to target the current
cost-effectiveness level while medical effectiveness and the price
of trastuzumab were used as variable parameters. RESULTS:
Trastuzumab treatment as in the HerA trial was very expensive
(37,980 €/patient). The product as such is expensive and treat-
ment is maintained for one year. The impact on total costs
depends on the percentage of patients being eligible for
trastuzumab treatment. Monthly treatment costs were largely
inﬂuenced by the discount ratio, the price of medication and the
ﬂow through of patients to metastatic treatment. According to
our threshold analysis, price discounts are indispensable to get
value for money unless great effectiveness improvements can be
realised. CONCLUSIONS: With a model reﬂecting real-world
conditions, cost implications of using trastuzumab in adjuvant
setting can be calculated before the product is widely spread.
When the ongoing trials cast light on new elements, new analy-
sis must be performed. The model provides essential information
for price-setting policies as well as for policymakers considering
reimbursement.
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ECONOMIC IMPACT OF PROSTATE-SPECIFIC ANTIGEN
DOUBLING TIME IN PATIENTS WITH HORMONE-
REFRACTORY PROSTATE CANCER
Mulani P1, Botteman M2, Hay JW3, Cifaldi M1
1Abbott Laboratories, Abbott Park, IL, USA; 2PharMerit North
America, Bethesda, MD, USA; 3University of Southern California,
Los Angeles, CA, USA
OBJECTIVE: There is limited information about cost implica-
tions of prostate-speciﬁc antigen doubling time (PSADT) in
patients with hormone-refractory prostate cancer (HRPCA).
This research was undertaken to assess the association between
PSADT <four-months with health care costs in HRPCA patients.
METHODS: A health care claims database (Pharmetrics®) 
with data from 70 managed care plans (1995–2002) was used.
HRPCA patients were identiﬁed using a pre-speciﬁed algorithm.
For each patient, we determined whether his PSADT was < or >
four-months. Costs were broken down by service type; manage-
ment, surgery, ancillary, facility and pharmacy. The costs of
HRPCA patients with PSADT < four-months were compared to
the cost of patients with PSADT > four-months. In addition, a
within-group analysis compared the cost of patients with PSADT
< four-months before and after reaching a PSADT < four-months
(the “event”). RESULTS: In total, 413 HRPCA patients were
identiﬁed, of which 71 HRPCA had PSADT < four-months. The
per-month health care cost (post-event) for patients who experi-
enced the event were, total $1524 (S.D.187.3), ancillary ($415
[56.1)), management ($471[69.4)), facility ($209 [47.5)), phar-
macy ($346 [33.3)), and surgery ($84 [27.9]), whereas the cor-
responding pre-event costs were, total ($1000 [141.1]) ancillary
($297 [89.2)), management ($205 [41.7]), facility ($25 [15.9]),
pharmacy ($436 [51.3]), and surgery ($37 [14.5)). The monthly
costs for patients who did not experience the event were total
$1064 [52.1], ancillary ($315 [20.6]), management ($319
[21.4)), facility ($115 [12.3)), pharmacy ($251 [10.2]), and
surgery ($64 [5.5]). Most of the between- and within-group com-
parisons were signiﬁcant (P < 0.05). CONCLUSION: HRPCA
patients with PSADT <four-months had signiﬁcantly higher
health care costs (post event). Therapies that extend PSADT have
a potential to show signiﬁcant cost savings.
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THE COST OF CANCER IN KOREA: 1999–2003
Jung YH, Ko S
Korea Institute for Health and Social Affairs, Seoul, South Korea
OBJECTIVE: Cancer has been the ﬁrst leading cause of death in
Korea. During the period of 1993~2003, the mortality rate of
cancer increased the most among the 10 major causes of death.
The aim of the study is to estimate the cost of cancer in Korea
during 1999~2003. METHODS: We estimate both direct and
indirect cost of cancer using a prevalence-based approach. Direct
cost estimates include medical expenditures, trafﬁc cost and care-
givers’ cost. Indirect costs representing the loss of productivity
are estimated based on human capital theory. The cost estimates
reported here are calculated at 0% discount rate. The major data
sources are National Health Insurance Statistical Yearbook,
Annual Report on the Cause of Death Statistics, and Survey
